Member Info for daveycaferacer

Thankyou doze, good article

I'd be interested in anyone's views on the Edison research note. The numbers as we go into the mid 2020's start to look extremely interesting. If even half the drug candidates get launched the revenue figures will be in the billions and the earnings will rise significantly. I hope the candidates we own outright, such as Sulfatinib remain wholly owned so we can enjoy the maximum possible economic benefit.

Thankyou Warsi - like you I am a very long term Investor, but made a catastrophic error selling my entire holding through boredom a few years ago, only to buy back at a much higher price. The lack of liquidity and CK’s Hutchison holding of 60% of shares has disadvantages but Edison also point out it's a feature of many Biopharmas. The fact the richest person in Asia who is considered to be an Asian version of Warren Buffet is heavily invested is a god sign. I do think many U.S. Investors do not like Chinese Companies although the fact we are not listed in China at all should give some comfort. We're also suffering from the fact the Biotech sector has been out of favour since the start of the year and the fact many IPO's were shelved, which probably explains why ours was done at such a discount. I've read the Edison note with great interest, however I think the numbers as we go forward beyond 2020 are where it will get extremely interesting.

indeed! certainly looking extremely interesting post 2018 as drug candidates get launched. I also like the fact we have some guidance on % royalties for drug sales in PRC and also rest of world. I was going to ask about that at the AGM but though that would put the Board in a difficult position as I assumed they would not really wish to disclose commercially confident information!

Anyone who is invested long term (I have a further 10 year timeline) will be significantly rewarded in my opinion

Excellent recent detailed research note from Edison http://www.edisoninvestmentresearch.com/research/report/hutchison-china-meditech11/preview/

Thanks Warwis - I am no expert but have a large holding in Chimed and agree with Mark Slater's views It seems to me that the Innovation part of the Business is still effectively valued at almost zero, a situation that will surely change over the next few years We have BT in a number of candidates and not all are partnered so we will enjoy maximum financial gain when things like Sulfatinib come to the market I mistakenly sold my entire holing at circa 450p a few years ago, a major error which I don't plan on repeating again. Our CEO interview with NASDAQ which is posted on our website is extremely informative and I think Christian sums up exactly where we are eg. at the start (not culmination, which is a bad word!). We are now after 16 years at the beginning of becoming a global scale Pharmaceutical Company based in China. I've never been invested at this stage in a Company that is profitable, very fast growing, has a clear strategy and a flawless execution record. The next few years will be absolutely groundbreaking IMO. Clearly the market does not quite agree with me............yet, but it will

I'm very surprised by the share price change over the last week in particular. We have a valuation lower than a year ago, yet we have a Company with $178m revenue, expected property windfalls in excess of $100m, a drug pipeline that is much more advanced than when it was valued 2 years ago with an rNPV of $942m, and possibility of NDA for Savolitinib. I do not understand why the ADR's are lower than the issue price or why the UK share price is significantly less than the equivalent 2 x ADR price. Separate markets and order books but it is still surprising to me.

I think someone did mention it but it wasn't discussed at length and the Company seems to have the view that once the U.S. Investor Community start to understand the Company and its potential over the next few years today's valuation will be a consigned to history. I gather that it should be viewed in the context that many Companies pulled their IPO's altogether in Q1 due to market conditions but it was decided ours should proceed due to the critical nature of getting some drug candidates launched, at least that's the impression I got. I also get the feeling and have done for a number of years that LONG TERM the Company will be valued at many many multiples of today's market cap, and long term Investors will be rewarded.

A private shareholder raised a question about the possibility of new Board members. That was asked in the context that the current BoD have been in place for a long time and have done an outstanding job but the gentleman in question wondered if some new talent may be needed as we enter a transformational time for the Company. Mrs Shih explained that the Board are considering possibly adding some new Directors and have identified some suitable candidates. There were other questions about the recent IPO and also general questions regarding pipeline progress. The Gentleman who asked about the BoD also raised some interesting points about the lack of liquidity and whether that was holding back the share price on the London market in particular.

I continue to buy at any price (within reason!) and have done today ;-)

Excellent AGM yesterday, very impressed as always with the Board and our CEO's presentation was very welcome. There is one particular aspect of our Company's strategy and vision which I like in particular and that is the dual focus of delivering value to Shareholders and also to patients. As someone whose wife died of cancer in 2009 I really do admire how Companies like Chi-Med are pushing the boundaries of science with targeted therapies. It really does look as if the Company will soon be evolving into a fully fledged Biopharma. Savolitinib for PRCC BT possibly by the end of the year. I still do not quite understand our market cap is much lower than some U.S. Biotechs that have much smaller pipelines that are often Pre-Clinical only and have no revenue and no profits! That will surely be corrected one day.....

Quiet period ends tomorrow, I think we can expect new research notes to start appearing quite soon now that the quiet period is ending. That should help to get word around about the Company and the fact it is on the cusp of becoming a major Biopharma in the next 2 or 3 years

agreed and I just think U.S. Investors will not buy anything that is Chinese especially if the Company name has China in it! Personally I think the fundamentals will win the day eventually, I mean, once our revenues are in $ billions and profits are in hundreds of millions it would be very off if we had this kind of market cap despite the fact we are Chinese.

I agree Matt, indeed that is the case and I can live with that, what I am irritated about is the pricing of the ADRs and the fact the U.S. market clearly doesn't yet see that this is currently very good value. Why for example is Beigene valued at almost $1bn when its pipeline is so small and it is still a long way away from Phase III or NDA;'s? There are numerous other Biopharmas with much bigger market caps than ours, but smaller revenues, debt, loss making and smaller pipelines. I don't quite get why the enormous near term potential is not being priced in here??

CEO - April 2014 - "We believe that the next 3, 4, 5 years are going to be transformational for us as a Company and that we will emerge as a truly global scale Biophamraceutical Company based in China"

An interview with our CEO has been posted on the Company website

I have a suspicion that now the overallotments have been taken up we may now move up from here

I spoke too soon, significant rise in ADR price wiped out in late trading

Finally today we are above the ADR issue price currently trading at $13.69 to buy Maybe the new Analyst coverage including that by Canacorrd has helped somewhat